论文部分内容阅读
丁胺卡那霉素为卡那霉素半合成衍生物,对革兰氏阴性杆茵有较强的抗菌活性,对卡那霉素、庆大霉索耐药菌株仍然有效。我院曾用苏州第一制药厂生产的丁胺卡那霉素试用于对氯霉素、庆大霉素等常用抗生素耐药的50例伤寒沙门菌感染的患者,并与氯霉素治疗组35例作对照,取得较满意的效果,现报道如下。 1 临床资料 一般资料:丁胺卡那霉素组,男20例,女30例。21个月～15岁13例,16～61岁37例。该组50例用其它抗生素治疗失败者33例,其中庆大霉素13例,氯霉素10例,磺卡青霉素2例,氨苄青霉素、复方新诺明、痢特灵等8例。合并患有胆囊炎者2例。氯霉素组35例,男16例,女19例;6～15岁5例,16～58岁30例;治疗前均未用过其它抗生素。
Amikacin is a semisynthetic derivative of kanamycin that has strong antibacterial activity against Gram-negative rods and is still effective against kanamycin and gentamycin-resistant strains. Our hospital had used the first pharmaceutical factory in Suzhou amikacin trial of chloramphenicol, gentamicin and other commonly used antibiotics resistant to 50 cases of Salmonella typhi infection in patients with chloramphenicol treatment group 35 cases as a control, to obtain more satisfactory results, are reported below. 1 Clinical data General information: amikacin group, 20 males and 30 females. 21 months to 15 years in 13 cases, 16 to 61 years in 37 cases. The group of 50 patients treated with other antibiotics failed in 33 cases, of which 13 cases of gentamicin, chloramphenicol 10 cases, 2 cases of sulfa penicillin, ampicillin, cotrimoxazole, furazolidone in 8 cases. In 2 cases with cholecystitis. Chloramphenicol group 35 cases, 16 males and 19 females; 6 to 15 years old in 5 cases, 16 to 58 years old in 30 cases; before treatment have not used any other antibiotics.